Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

AUPH · Nasdaq

Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Aurinia Pharmaceuticals Inc. in 2026. The next earnings report is expected on October 29, 2026.

Earnings calendar

Next earnings date

29 Oct 2026

In 70 days

EPS estimate

0.24

Revenue estimate

83.1M

Past earnings

06 Aug 2026
EPS actual
0.28 (+5.7%)
estimate 0.27
Revenue actual
83.2M (+1.8%)
estimate 81.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
0.25 (+28.2%)
estimate 0.20
Revenue actual
77.7M (+0.9%)
estimate 77.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 May 2026
EPS actual
—
estimate 0.20
Revenue actual
—
estimate 77.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Feb 2026
EPS actual
1.53 (+606.2%)
estimate 0.22
Revenue actual
77.1M (+3.2%)
estimate 74.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Aurinia Pharmaceuticals Inc. beat consensus estimates in its latest earnings report, with EPS of $0.28 coming in 5.7% above expectations and revenue of $83.22 million exceeding estimates by 1.8%. Both EPS and revenue were also ahead of expectations in the prior quarter.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
Nasdaq
CEO
Peter S. Greenleaf
Employees
130
IPO date
03 Sep 2014
ISIN
CA05156V1022
Website
auriniapharma.com

Frequently asked questions

When does Aurinia Pharmaceuticals Inc. (AUPH) next report earnings?

Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to report earnings on October 29, 2026.

What was Aurinia Pharmaceuticals Inc.'s most recent earnings date?

Aurinia Pharmaceuticals Inc. (AUPH) last reported earnings on August 6, 2026.

Where is Aurinia Pharmaceuticals Inc. stock listed?

Aurinia Pharmaceuticals Inc. (AUPH) is listed on Nasdaq.